Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

David Seftel, David R. Boulware

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.

Original languageEnglish (US)
Article numberofab050
JournalOpen Forum Infectious Diseases
Volume8
Issue number2
DOIs
StatePublished - Feb 1 2021

Bibliographical note

Publisher Copyright:
© 2021 The Author(s).

Keywords

  • COVID-19
  • SARS-COV-2
  • cohort
  • coronavirus
  • fluvoxamine

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19'. Together they form a unique fingerprint.

Cite this